Challenges in searching for therapeutics against Botulinum Neurotoxins. (4th May 2017)

• Record Type: Journal Article
• Authors: Pirazzini, Marco; Rossetto, Ornella
• Is Part Of: Expert opinion on drug discovery. Volume 12:Number 5(2017:May)
• Page Start: 497
• Page End: 510
• Publication Date: 2017-05-04
• Subjects: Botulinum Neurotoxins -- bioterrorism -- bioweapon -- clostridium -- pan-inhibitors -- serotypes -- subtypes -- thioredoxin -- neuromuscular junction -- neuroparalysis; 615.1
• DOI: 10.1080/17460441.2017.1303476
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Botulinum neurotoxins (BoNTs) are the most potent toxins known. BoNTs are responsible for botulism, a deadly neuroparalytic syndrome caused by the inactivation of neurotransmitter release at peripheral nerve terminals. Thanks to their specificity and potency, BoNTs are both considered potential bio-weapons and therapeutics of choice for a variety of medical syndromes. Several variants of BoNTs have been identified with individual biological properties and little antigenic relation. This expands greatly the potential of BoNTs as therapeutics but poses a major safety problem, increasing the need for finding appropriate antidotes. Areas covered : The authors describe the multi-step molecular mechanism through which BoNTs enter nerve terminals and discuss the many levels at which the toxins can be inhibited. They review the outcomes of the different strategies adopted to limit neurotoxicity and counter intoxication. Potential new targets arising from the last discoveries of the mechanism of action and the approaches to promote neuromuscular junction recovery are also discussed. Expert opinion : Current drug discovery efforts have mainly focused on BoNT type A and addressed primarily light chain proteolytic activity. Development of pan-BoNT inhibitors acting independently of BoNT immunological properties and targeting a common step of the intoxication process should be encouraged.